Karolinska Development AB: Pergamum Announces That the First Patient has Been Dosed With Potential New Treatment for Hard-to-Heal Wounds

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers. Karolinska Development AB (STO: KDEV) is the majority owner of Pergamum. "Non-healing wounds are a huge burden for the individual patient and for the health care system. Today, there are an estimated 15 million patients globally, and virtually no medical progress has been made over the last few decades", said Jonas Ekblom, CEO of Pergamum AB. "This clinical trial will allow us to evaluate a promising new treatment, based on the body’s own immune defense, for patients with venous leg ulcers. The ultimate goal is to accomplish faster healing and improved quality of life for patients who typically have a poor prognosis."